...
首页> 外文期刊>Cytotherapy >Enrichment of vascular endothelial growth factor secreting mesenchymal stromal cells enhances therapeutic angiogenesis in a mouse model of hind limb ischemia
【24h】

Enrichment of vascular endothelial growth factor secreting mesenchymal stromal cells enhances therapeutic angiogenesis in a mouse model of hind limb ischemia

机译:血管内皮生长因子分泌间充质基质细胞的富集增强了后肢缺血小鼠模型中的治疗血管生成

获取原文
获取原文并翻译 | 示例
           

摘要

Critical limb ischemia, a severe manifestation of peripheral artery disease, is emerging as a major concern in aging societies worldwide. Notably, cell-based gene therapy to induce angiogenesis in ischemic tissue has been investigated as treatment. Despite many studies demonstrating the efficacy of this approach, better therapies are required to prevent serious sequelae such as claudication, amputation and other cardiovascular events. We have now established a simplified method to enhance the effects of therapeutic transgenes by selecting for and transplanting only transduced cells. Herein, mesenchymal stromal cells were transfected to co-express vascular endothelial growth factor as angiogenic factor and enhanced green fluorescent protein as marker. Transfected cells were then collected using flow cytometry based on green fluorescence and transplanted into ischemic hind limbs in mice. Compared with unsorted or untransfected cells, purified cells significantly improved blood perfusion within 21 days, suggesting that transplanting only cells that overexpress vascular endothelial growth factor enhances therapeutic angiogenesis. Importantly, this approach may prove to be useful in cell-based gene therapy against a wide spectrum of diseases, simply by replacing the gene to be delivered or the cell to be transplanted.
机译:临界肢体缺血,严重表现出外周血动脉疾病,是全球老龄化社会的主要关注点。值得注意的是,研究了基于细胞的基因治疗,以诱导缺血组织中的血管生成作为治疗。尽管许多研究表明这种方法的功效,但需要更好的疗法来防止严重的后遗症,例如跛行,截肢和其他心血管事件。我们现在建立了一种简化的方法,通过选择和移植转导细胞来增强治疗转基因的影响。在此,将间充质基质细胞转染以将与血管生成因子的共表达血管内皮生长因子和增强的绿色荧光蛋白作为标记。然后使用基于绿色荧光的流式细胞术收集转染的细胞,并在小鼠中移植到缺血性后肢中。与未缺陷或未转化的细胞相比,纯化细胞在21天内显着改善血液灌注,表明仅移植过表达血管内皮生长因子的细胞增强治疗血管生成。重要的是,这种方法可以证明在基于细胞的基因疗法中可用于针对广谱疾病的基础疗法,只需通过替换待递送的基因或待移植的细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号